The HIF-1-active microenvironment: An environmental target for cancer therapy

Advanced Drug Delivery Reviews

Volumn 61, Issue 7-8, 2009, Pages 623-632

  Kizaka Kondoh, Shinae ^a   Tanaka, Shotaro ^a   Harada, Hiroshi ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bioluminescence; Gene therapy; Gene Directed Enzyme Prodrug Therapy (GDEPT); Hypoxia inducible factor 1 (HIF 1); Hypoxia responsive element (HRE); In vivo imaging; Protein transduction domain (PTD); Tumor hypoxia

Indexed keywords

GENE THERAPY; HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1); HYPOXIA-RESPONSIVE ELEMENT (HRE); IN VIVO IMAGING; PROTEIN TRANSDUCTION DOMAIN (PTD); TUMOR HYPOXIA;

BACTERIOPHAGES; BIOLUMINESCENCE; ENZYMES; GENETIC ENGINEERING; LIGHT EMISSION; PHOSPHORESCENCE; TRANSCRIPTION FACTORS; TUMORS;

TRANSCRIPTION;

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 REDUCTASE; CYTOSINE DEAMINASE; ENOLASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FACTOR INHIBITING HIF; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; MAMMALIAN TARGET OF RAPAMYCIN; MITOMYCIN C; OXYGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C RECEPTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

BIOLUMINESCENCE; BREAST CANCER; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER RECURRENCE; CELL HYPOXIA; COLON CANCER; DRUG TARGETING; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE INDUCTION; HUMAN; KIDNEY CARCINOMA; MELANOMA; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; UTERINE CERVIX CANCER;

ANIMALS; ANOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 65749102069     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.01.006     Document Type: Review

References (62)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14 (2004) 198-206
2. Brown J.M., and Wilson W.R. Exploiting tumor hypoxia in cancer treatment. Nat. Rev., Cancer 4 (2004) 437-447
3. Harris A.L. Hypoxia - a key regulator factor in tumor growth. Nat. Rev., Cancer 2 (2002) 38-47
4. Semenza G. Targeting HIF-1 for cancer therapy. Nat. Rev., Cancer 3 (2003) 721-732
5. Raleigh J.A., Chou S.C., Arteel G.E., and Horsman M.R. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat. Res. 151 (1999) 580-589
6. Vordermark D., and Brown J.M. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?. Strahlenther. Onkol. 179 (2003) 801-811
7. Sobhanifar S., Aquino-Parsons C., Stanbridge E.J., and Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 65 (2005) 7259-7266
8. Janssen H.L., Haustermans K.M., Balm A.J., and Begg A.C. Hypoxia in head and neck cancer: how much, how important?. Head Neck 27 (2005) 622-638
9. 2 tension. Am. J. Physiol. 271 (1996) C1172-C1180
10. Epstein A.C., Gleadle J.M., McNeil L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., and Ratcliffe P.J. C. elegans and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
11. Knowles H.J., Raval R.R., Harris A.L., and Rateliffe P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63 (2003) 1764-1768
12. 2 sensing. Science 292 (2001) 464-468
13. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
14. Maxwell P.H., Wiesener M., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
15. Liu Y.V., and Semenza G.L. RACK1 vs HSP90: competition for HIF-1 alpha degradation vs stabilization. Cell Cycle 6 (2007) 656-659
16. Mohon P.C., Hirota K., and Semenza G.L. FIH-1: a novel protein that interacts with HIF-1 alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
17. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
18. Koivunen P., Hirsila M., Gunzler V., Kivinkko K.I., and Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279 (2004) 9899-9904
19. Hirsila M., Koivunen P., Gunzler V., Kivinkko K.I., and Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278 (2003) 30772-30780
20. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277 (2002) 38205-38211
21. Semenza G.L. Hypoxia-inducible Factor 1 and Cancer Pathogenesis. IUBMB Life 60 (2008) 591-597
22. Fukuda R., Kelly B., and Semenza G.L. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E is mediated by hypoxia-inducible factor 1. Cancer Res. 63 (2003) 2330-2334
23. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001) 3995-4004
24. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 60 (2000) 1541-1545
25. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
26. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 12 (2007) 853-859
27. Schmid T., Zhou J., and Brüne B. HIF-1 and p53: communication of transcription factors under hypoxia. J. Cell. Mol. Med. 8 (2004) 423-431
28. Arany Z., Haung E.L., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., Bunn H.F., and Livingston D.M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. UST 93 (1996) 12969-12973
29. Ruas J.L., and Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin. Cell Dev. Biol. 16 (2005) 514-522
30. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concordet J.P., Maire P., and Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271 (1996) 32529-32537
31. O'Rourke J.F., Dachs G.U., Gleadle J.M., Maxwell P.H., Pugh C.W., Stratford I.J., Wood S.M., and Ratchliffe P.J. Hypoxia response elements. Oncol. Res. 9 (1997) 327-332
32. Greco O., Patterson A.V., and Dachs G.U. Can gene therapy overcome the problem of hypoxia in radiotherapy?. J. Radiat. Res. 41 (2000) 201-212
33. Shibata T., Akiyama N., Noda M., Sasai K., and Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 913-916
34. Shibata T., Giaccia A.J., and Brown J.M. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 7 (2000) 493-498
35. Ruan H., Su H., Hu L., Lamborn K.R., Kan Y.W., and Deen D.F. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 3 (2001) 255-263
36. Binley K., Askham Z., Martin L., Spearman H., Day D., Kingsman S., and Naylor S. Hypoxia-mediated tumor targeting. Gene Ther. 10 (2003) 540-549
37. Kizaka-Kondoh S., Inoue M., Harada H., and Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 94 (2003) 1021-1028
38. Greco O., Marples B., Joiner M.C., and Scott S.D. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J. Cell. Physiol. 197 (2003) 312-325
39. Liu J., Harada H., Ogura M., Shibata T., and Hiraoka M. Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumor xenografts. Br. J. Cancer 96 (2007) 1871-1878
40. Shibata T., Giaccia A.J., and Brown J.M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4 (2002) 40-48
41. Ogura M., Shibata T., Yi J., Liu J., Qu R., Harada H., and Hiraoka M. A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas. Cancer Sci. 96 (2005) 288-294
42. Patterson A.V., Williams K.J., Cowen R.L., Jaffar M., Telfer B.A., Saunders M., Airley R., Honess D., van der Kogel A.J., Wolf C.R., and Stratford I.J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumors. Gene Ther. 9 (2002) 946-954
43. Post D.E., and Van Meir E.G. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22 (2003) 2065-2072
44. Hernandez-Alcoceba R., Pihalja M., Qian D., and Clarke M.F. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum. Gene Ther. 13 (2002) 1737-1750
45. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., and Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15155-15160
46. Nakamura T., Sasaki T., Fujimori M., Yazawa K., Kano Y., Amano J., and Taniguchi S. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci. Biotechnol. Biochem. 66 (2002) 2362-2366
47. Liu S.C., Minton N.P., Giaccia A.J., and Brown J.M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 9 (2002) 291-296
48. McCarthy H.O., Yakkundi A., McErlane V., Hughes C.M., Keilty G., Murray M., Patterson L.H., Hirst D.G., McKeown S.R., and Robson T. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 10 (2003) 40-48
49. Kaliberov S.A., Buchsbaum D.J., Gillespie G.Y., Curiel D.T., Arafat W.O., Carpenter M., and Stackhouse M.A. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol. Ther. 6 (2002) 190-198
50. Vordermark D., Kraft P., Katzer A., Bölling T., Willner J., and Flentje M. Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). Cancer Lett. 230 (2005) 122-133
51. Liu J., Qu R., Ogura M., Shibata T., Harada H., and Hiraoka M. Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J. Radiat. Res. 46 (2005) 93-102
52. Cao Y., Li C.Y., Moeller B.J., Yu D., Zhao Y., Dreher M.R., Shan S., and Dewhirst M.W. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res. 65 (2005) 5498-5505
53. Harada H., Kizaka-Kondoh S., Itasaka S., Shibuya K., Morinibu A., Shinomiya K., and Hiraoka M. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem. Biophys. Res. Commun. 360 (2007) 791-796
54. Sadikot R.T., and Blackwell T.S. Bioluminescence imaging. Proc. Am. Thorac. Soc. 2 (2005) 537-540
55. Harada H., Kizaka-Kondoh S., and Hiraoka M. Optical Imaging of Tumor Hypoxia and Evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol. Imaging 4 (2005) 182-193
56. Harada H., Kizaka-Kondoh S., Li G., Itasaka S., Shibuya K., Inoue M., and Hiraoka M. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26 (2007) 7508-7516
57. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., and Dewhirst M.W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
58. Harada H., Hiraoka M., and Kizaka-Kondoh S. Anti-tumor effect of TAT-ODD-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. 62 (2002) 2013-2018
59. Harada H., Kizaka-Kondoh S., and Hiraoka M. Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1α containing Pro564. FEBS Lett. 580 (2006) 5718-5722
60. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
61. Inoue M., Mukai M., Hamanaka Y., Tatsuta M., Hiraoka M., and Kizaka-Kondoh S. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int. J. Oncol. 25 (2004) 713-720
62. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., and Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 67 (2007) 4157-4163